Welcome to our dedicated page for Procter & Gamble SEC filings (Ticker: PG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Procter & Gamble Company (PG) files a wide range of documents with the U.S. Securities and Exchange Commission, providing detailed insight into its operations, capital structure, governance, and shareholder policies. As a New York Stock Exchange‑listed issuer with common stock and multiple series of notes registered under Section 12(b) of the Exchange Act, P&G uses SEC filings to report material events, financing activities, executive and director matters, and shareholder meeting results.
Recent Form 8‑K filings illustrate the types of information investors can find. Regulation FD 8‑Ks document quarterly dividend declarations on common stock and ESOP convertible preferred stock, along with the company’s long record of consecutive dividend payments and increases. Other 8‑Ks report underwritten public offerings of U.S. dollar, euro, and pound sterling notes with various maturities, including floating rate notes and fixed‑rate notes issued under a shelf registration statement on Form S‑3, with related legal opinions filed as exhibits.
Additional 8‑Ks address governance topics such as the approval of The Procter & Gamble 2025 Stock and Incentive Compensation Plan, voting results from the Annual Meeting of Shareholders, and retirement announcements for senior executives. Earnings‑related 8‑Ks furnish quarterly results, slides used on earnings calls, and notices of webcasts. Together with the company’s proxy statement on Schedule 14A, these filings give a structured view of P&G’s executive compensation framework, board composition, and strategic priorities.
On this page, Stock Titan provides real‑time access to Procter & Gamble’s SEC filings as they appear on EDGAR, along with AI‑powered summaries to help explain the significance of each document. Users can quickly review annual and quarterly reports, current reports on Form 8‑K, and exhibits related to new debt offerings or compensation plans, as well as monitor items such as dividend announcements and shareholder vote outcomes without reading every page of the underlying filings.
PROCTER & GAMBLE Co executive Francisco Ma. Fatima, CEO of Baby, Fem & Family Care, reported multiple stock moves. On
She also received a grant of 57.0033 Restricted Stock Units on
PROCTER & GAMBLE Co executive Susan Street Whaley reported both a stock sale and an equity award. On February 19, 2026, she completed an open-market sale of 1,809 shares of common stock at an average price of $159.4551 per share.
After this sale, her directly held common stock position was 30,215.0293 shares. She also had 6,589.6417 shares held indirectly through a retirement plan trustee. On February 17, 2026, she acquired 11.485 restricted stock units at no cost, increasing her RSU balance to 65.1290 units, which are scheduled to settle in Procter & Gamble common stock, generally in connection with retirement.
Morgan Stanley Smith Barney LLC files a Form 144 reporting proposed sales of Procter & Gamble common stock. The notice lists 1,400 shares tied to a Restricted Stock Unit Award dated 10/01/2021 and 1,493 shares from a Performance Stock Program Award dated 08/19/2024.
Procter & Gamble's Chief Research, Development & Innovation Officer, Aguilar Moses Victor Javier, exercised stock options and sold shares on February 13, 2026. He exercised 15,169 stock options at an exercise price of $91.07 per share, receiving the same number of common shares.
On the same day, he sold 15,169 common shares in an open-market transaction at a weighted average price of $162.2789 per share, within a price range of $162.26 to $162.311. Following these transactions, he held 44,735.4826 common shares directly, plus additional indirect holdings through a retirement plan and an international stock ownership plan.
Procter & Gamble’s Chief Human Resources Officer, Purushothaman Balaji, reported an option exercise and share sale on February 11, 2026. He exercised a stock option for 12,827 shares of common stock at an exercise price of
On the same day, he sold 12,827 common shares in an open-market transaction at a weighted average price of
Procter & Gamble executive chair Jon R. Moeller, who also serves as a director, reported option exercises and share sales in February 2026. On February 11, he exercised options for 11,036 common shares at
Procter & Gamble CEO – Grooming Gary A. Coombe reported multiple equity transactions in Procter & Gamble common stock. On February 12, 2026, he exercised stock options for 36,093 shares at an exercise price of $78.52 per share, receiving the same number of common shares.
On the same date, he then sold 36,093 common shares in open-market transactions at a weighted average price of $162.3307, leaving 34,993.7893 shares of directly held common stock. He also reports indirect holdings of 486.4342 shares through a retirement plan trustee and 1,295.35 shares through an international stock ownership and pension plan.
In addition, previously granted restricted stock units, including 63.6893 units awarded on November 17, 2025, total 1,117.3663 RSUs. Footnotes explain that these RSUs and some share totals include dividend equivalents and may be delivered in shares upon retirement under the company’s programs.
The Procter & Gamble Company investor files a notice to sell restricted shares under Rule 144. The planned transaction covers 15,169 shares of common stock with an aggregate market value of $2,448,124.91, to be executed through Morgan Stanley Smith Barney LLC on the NYSE.
The shares were acquired and paid for in cash on 02/13/2026 through an exercise and sale of stock options. The filing also notes that Procter & Gamble had 2,324,000,685 shares of common stock outstanding, providing context for the size of this proposed sale.
An insider of Procter & Gamble plans to sell 12,827 shares of common stock under Rule 144. The planned sale has an aggregate market value of $2,022,176.55 and is scheduled for 02/11/2026 on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.
The shares will come from the exercise and sale of a stock option, paid in cash on 02/11/2026. The filing notes that Procter & Gamble has 2,324,000,685 common shares outstanding, which provides scale for the size of this planned transaction.
The Procter & Gamble Company has a shareholder filing a notice of proposed sale of 173,268 shares of common stock, with an aggregate market value of $27,315,700.20. The planned sale is tied to the exercise and sale of a stock option on 02/11/2026.
The shares are to be sold for cash through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. The filing notes total common shares outstanding of 2,324,000,685 and includes a representation that the seller is not aware of undisclosed material adverse information about Procter & Gamble.